Craig Hallum Begins Coverage on Satellos Bioscience (NASDAQ:MSLE)

Research analysts at Craig Hallum initiated coverage on shares of Satellos Bioscience (NASDAQ:MSLE) in a research note issued on Thursday, Benzinga reports. The firm set a “buy” rating and a $24.00 price target on the stock. Craig Hallum’s price target indicates a potential upside of 225.87% from the company’s current price.

MSLE has been the subject of a number of other reports. Wells Fargo & Company set a $18.00 target price on shares of Satellos Bioscience in a report on Thursday, July 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Friday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Satellos Bioscience in a research note on Monday, August 17th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Satellos Bioscience has an average rating of “Moderate Buy” and an average price target of $20.60.

Satellos Bioscience Trading Down 3.5%

Shares of NASDAQ:MSLE traded down $0.27 during trading on Thursday, reaching $7.37. The company had a trading volume of 23,735 shares, compared to its average volume of 56,386. The stock has a market capitalization of $156.29 million, a P/E ratio of -3.84 and a beta of 1.51. The company has a fifty day moving average of $9.33 and a two-hundred day moving average of $7.99. Satellos Bioscience has a 12 month low of $5.30 and a 12 month high of $13.39.

Satellos Bioscience (NASDAQ:MSLE) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.18). As a group, equities research analysts predict that Satellos Bioscience will post -1.86 earnings per share for the current year.

Institutional Investors Weigh In On Satellos Bioscience

An institutional investor recently raised its position in Satellos Bioscience stock. Stonepine Capital Management LLC boosted its stake in shares of Satellos Bioscience Inc. (NASDAQ:MSLE) by 391.6% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 491,624 shares of the company’s stock after purchasing an additional 391,624 shares during the period. Satellos Bioscience makes up approximately 0.0% of Stonepine Capital Management LLC’s portfolio, making the stock its 16th biggest holding. Stonepine Capital Management LLC owned 2.36% of Satellos Bioscience worth $3,723,291 as of its most recent filing with the SEC.

Satellos Bioscience Company Profile

Satellos Bioscience Corporation (NASDAQ:MSLE) is a biotechnology company focused on developing therapies that promote the natural regeneration and repair of skeletal muscle. Its research is based on the role of muscle stem cells, also known as satellite cells, in maintaining and rebuilding muscle tissue after injury or disease.

The company’s lead program is SAT-3247, an investigational small-molecule therapy being developed for muscle-wasting disorders, including Duchenne muscular dystrophy.